(Q42364156)

28 October 2017

0 references

Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma (English)

1 reference

28 October 2017

1 reference

1 reference

3

David Reardon

1 reference

28 October 2017

Gordana Vlahovic

1

1 reference

28 October 2017

Peter E Fecci

series ordinal

2

1 reference

28 October 2017

John H Sampson

series ordinal

4

1 reference

28 October 2017

language of work or name

1 reference

10 May 2015

1 reference

28 October 2017

1 reference

28 October 2017

17

1 reference

28 October 2017

8

1 reference

28 October 2017

1043-1045

1 reference

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

28 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Hematogenous dissemination of glioblastoma multiforme.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Programmed death ligand-1 expression in non-small cell lung cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Oncology meets immunology: the cancer-immunity cycle

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

The blockade of immune checkpoints in cancer immunotherapy

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

CNS immune privilege: hiding in plain sight

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490880

17 August 2018

Identifiers

DOI

10.1093/NEUONC/NOV071

1 reference

28 October 2017

1 reference

28 October 2017

PubMed publication ID

25964311

1 reference